Precision therapy company leveraging its ‘click-2-release’ technology platform to unlock full potential of systemic therapies by improving therapeutic window and improving standard of care for patients suffering from severe diseases including cancer.

Sectors
Biopharma
Healthcare
Life Sciences
First Invested
2023
Early
Company Status
Board Members
Michele Park, PhD